Skip to content

Impact of a Mobility Program

Impact of a Hospital Mobility Program on Function After Discharge

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02674503
Enrollment
132
Registered
2016-02-04
Start date
2016-12-12
Completion date
2021-09-30
Last updated
2024-07-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hospitalization

Keywords

Walking, Hospitalization, Randomized controlled trial

Brief summary

After hospitalization, many older adults experience more difficulty getting around in the community and performing one or more of their basic activities of daily living (ADLs) like bathing or dressing. The goals of this study are to test the effectiveness of a mobility intervention, compared to usual care, on change in mobility after hospitalization, to determine the impact on one-year outcomes such as nursing home placement and to identify which Veterans benefit the most from the intervention. Ultimately, the goal is to improve recovery after hospitalization and reduce disability in hospitalized Veterans.

Detailed description

For this high impact study the investigators propose to use a stepped wedge cluster randomization design on five VA hospital wards to compare a mobility program (MP) to usual care (UC) among a cohort of Veterans age 50 years. The investigators will examine pre to post-hospital mobility and adverse outcomes including functional decline, nursing home admission, emergency department (ED) visits, hospitalization and death in the MP and UC groups in the year after hospital discharge. The primary outcome of mobility will be measured by the University of Alabama at Birmingham (UAB) Life-Space Assessment (LSA).10-13 Secondary measures of mobility will include self-reported ability to walk mile and drive a car, as described by Gill, et al.14 The investigators will identify patient specific characteristics that modify the effect of the mobility intervention on post-hospital mobility and adverse outcomes to determine which hospitalized patients are most likely to benefit from this intervention. Note, Secondary outcome measures were curtailed as the original PI, Dr. Brown, retired.

Interventions

BEHAVIORALWalking

MP patients will participate in a program of progressive walking and transfer training up to three times a day, seven days a week throughout the hospital stay. MP patients will begin with assisted sitting, then standing, progressing to weight shifting and stepping in place, and then to walking as tolerated. The level of mobility recommended to the MP patient by the Walker will be dependent on the individual patient and will incorporate the activities patients were deemed able to do independent of cueing or assistance during each walking session.

BEHAVIORALFriendly visit

UC patients will receive three times a day friendly visits, seven days a week by members of the research team to control for the daily attention that MP patients receive.

Sponsors

VA Office of Research and Development
Lead SponsorFED

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
50 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Age 50 years admitted to one of the five hospital wards of the Birmingham VA Medical Center (VAMC) for any medical illness, e.g.: * Pneumonia * Heart failure * Chronic obstructive pulmonary disease (COPD) exacerbation * Or other medical (versus surgical) indication for hospitalization * Patients will be recruited within 48 hours of hospitalization, followed throughout their hospitalization and for one year after hospital discharge.

Exclusion criteria

* Patients admitted for brief observation will be excluded, e.g.: * 23-hour observation for possible myocardial infarction * Additional

Design outcomes

Primary

MeasureTime frameDescription
Life-Space Assessment ScoreOne yearThe UAB Study of Aging Life-Space Assessment (LSA) is a validated tool that measures mobility and function based on the distance which a person reports moving during the four weeks preceding the assessment. The range in scores is 0-100 with higher scores representing better life space mobility.

Secondary

MeasureTime frameDescription
Activities of Daily Living (ADLs)One YearParticipants will be asked to complete the Katz ADL. Specifically, patients will be asked to rate their current level of independence with six activities of daily living (feeding, bathing, dressing, toileting, transferring, and walking across a small room). Scores range from 0-12, with lower scores representing better independence in activities of daily living.
Presence of Adverse Outcomes: Nursing Home PlacementOne yearTo determine the impact of participation in the mobility program on adverse outcomes, the investigators will measure the frequency of nursing home placement in the MP versus UC groups.
Presence of Adverse Outcomes: DeathOne yearTo determine the impact of participation in the mobility program on adverse outcomes, the investigators will measure the frequency of death in the MP versus UC groups.
Presence of Adverse Outcomes (ED Visits, Rehospitalization, Nursing Home Placement, Death)One yearTo determine the impact of participation in the mobility program on adverse outcomes, the investigators will measure the frequency of ED visits, hospitalizations as well as death and nursing home admissions including both short and long term placement in the MP versus UC groups.
Instrumental Activities of Daily Living (IADLs)One yearLevel of independence with Instrumental Activities of Daily Living (IADLs) will be assessed at the same time points as the basic ADLs using the Lawton Index. The IADL index evaluates 8 domains of function including shopping, food preparation, housekeeping, laundry, transportation, handling finances, ability to take own medications and use of the telephone. A summary score ranges from 3 to 24, with higher scores indicating higher levels of independence with the tasks. Score options were trichotomous (1 = unable, 2 = needs assistance, 3 = independent).
Presence of Adverse Outcomes: RehospitalizationOne YearTo determine the impact of participation in the mobility program on adverse outcomes, the investigators will measure the frequency of rehospitalization in the MP versus UC groups.
Confusion Assessment MethodBaseline onlyThe Confusion Assessment Method (CAM) allows rapid assessment of the presence of delirium. Four clinical features, including 1) Acute onset and fluctuating course; 2) Inattention; 3) Disorganized thinking; and 4) Altered level of consciousness, are assessed. The presence of features 1 and 2 and either 3 or 4 indicates the patient has delirium. The positive and negative predictive values for the CAM are approximately 90%.
Patient Health Questionnaire (PHQ) -2One yearPatients will be asked at each interview the Patient Health Questionnaire (PHQ) - 2, specifically 1) Have you often been bothered by feeling down, depressed, or hopeless?; and 2) Have you often been bothered by little interest or pleasure in doing things? The PHQ-2 has been found to have a sensitivity and specificity of 83% and 92% respectively and is an excellent brief screening tool for depression.
EuroQOL Five Dimensions Questionnaire (EQ-5D)One yearPatients will be asked to complete the EQ-5D once during the hospital stay, then at months 1, 3, 6, 9, and 12. The EQ-5D-3L is a well-validated measure of quality of life which enables the calculation of a single index value ranging from 0, worst imaginable health to 1, perfect health.
Lubben Social Network Scale (LSNS-Revised)One yearThe Lubben Social Network Scale (LSNS) was designed to measure perceived social support received from family and friends. The LSNS-Revised includes 12 items with scores ranging from 0-60 with higher scores indicating greater perceived social support.
Level of Hospital MobilityAverage one weekAll patients will wear a StepWatch throughout the hospitalization to document the level of mobility attained by each patient. The StepWatch is a ankle worn pedometer that documents number of steps taken and when they were taken.
Mini Cognitive Assessment (Mini-Cog)Baseline onlyThe Mini-Cog is a brief cognitive screening measure that includes a three-item memory recall and a clock drawing test. The test is scored using a simple algorithm whereby patients who are unable to recall any of the three items are considered demented; those who can recall all three items are deemed not demented; and those with intermediate word recall ability (1 or 2 items) are classified based on the clock drawing test. For persons with intermediate recall ability, if the clock drawing is abnormal, the patient is considered demented and if the clock drawing is normal the patient is not considered demented.

Countries

United States

Participant flow

Recruitment details

Dates of recruitment were 12/12/2016 through 10/19/2019. Participant recruited from the inpatient hospital setting.

Pre-assignment details

No significant events in the study that occurred after participant enrollment.

Participants by arm

ArmCount
Intensive
MP patients will participate in a program of progressive walking and transfer training up to three times a day, seven days a week throughout the hospital stay. Walking: MP patients will participate in a program of progressive walking and transfer training up to three times a day, seven days a week throughout the hospital stay. MP patients will begin with assisted sitting, then standing, progressing to weight shifting and stepping in place, and then to walking as tolerated. The level of mobility recommended to the MP patient by the Walker will be dependent on the individual patient and will incorporate the activities patients were deemed able to do independent of cueing or assistance during each walking session.
60
Friendly Visit
UC patients will receive three times a day friendly visits, seven days a week by members of the research team to control for the daily attention that MP patients receive. Friendly visit: UC patients will receive three times a day friendly visits, seven days a week by members of the research team to control for the daily attention that MP patients receive.
68
Total128

Baseline characteristics

CharacteristicTotalIntensiveFriendly Visit
Activities of Daily Living Score, mean (SD)7.5 units on a scale
STANDARD_DEVIATION 1.6
7.5 units on a scale
STANDARD_DEVIATION 1.3
7.6 units on a scale
STANDARD_DEVIATION 1.8
Age, Continuous66.2 years
STANDARD_DEVIATION 9
66.2 years
STANDARD_DEVIATION 8.5
66.2 years
STANDARD_DEVIATION 9.5
Ethnicity (NIH/OMB)
Hispanic or Latino
2 Participants2 Participants0 Participants
Ethnicity (NIH/OMB)
Not Hispanic or Latino
122 Participants56 Participants66 Participants
Ethnicity (NIH/OMB)
Unknown or Not Reported
4 Participants2 Participants2 Participants
Instrumental Activities of Daily Living Score, mean (SD)14.8 units on a scale
STANDARD_DEVIATION 2.3
14.7 units on a scale
STANDARD_DEVIATION 2.4
14.9 units on a scale
STANDARD_DEVIATION 2.2
Life Space Total Score, mean (SD)63.5 units on a scale
STANDARD_DEVIATION 25.8
60.1 units on a scale
STANDARD_DEVIATION 28.3
66.5 units on a scale
STANDARD_DEVIATION 23.2
Race (NIH/OMB)
American Indian or Alaska Native
2 Participants1 Participants1 Participants
Race (NIH/OMB)
Asian
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Black or African American
51 Participants25 Participants26 Participants
Race (NIH/OMB)
More than one race
3 Participants2 Participants1 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Unknown or Not Reported
4 Participants2 Participants2 Participants
Race (NIH/OMB)
White
68 Participants30 Participants38 Participants
Region of Enrollment
United States
128 Participants60 Participants68 Participants
Sex: Female, Male
Female
15 Participants10 Participants5 Participants
Sex: Female, Male
Male
113 Participants50 Participants63 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
10 / 609 / 68
other
Total, other adverse events
11 / 6024 / 68
serious
Total, serious adverse events
36 / 6027 / 68

Outcome results

Primary

Life-Space Assessment Score

The UAB Study of Aging Life-Space Assessment (LSA) is a validated tool that measures mobility and function based on the distance which a person reports moving during the four weeks preceding the assessment. The range in scores is 0-100 with higher scores representing better life space mobility.

Time frame: One year

ArmMeasureValue (MEAN)Dispersion
IntensiveLife-Space Assessment Score57.8 score on a scaleStandard Deviation 26.7
Friendly VisitLife-Space Assessment Score59.6 score on a scaleStandard Deviation 23.3
p-value: 0.02Regression, Linear
Secondary

Activities of Daily Living (ADLs)

Participants will be asked to complete the Katz ADL. Specifically, patients will be asked to rate their current level of independence with six activities of daily living (feeding, bathing, dressing, toileting, transferring, and walking across a small room). Scores range from 0-12, with lower scores representing better independence in activities of daily living.

Time frame: One Year

ArmMeasureValue (MEAN)Dispersion
IntensiveActivities of Daily Living (ADLs)7.34 score on a scaleStandard Deviation 0.97
Friendly VisitActivities of Daily Living (ADLs)7.37 score on a scaleStandard Deviation 0.76
p-value: 0.13Regression, Linear
Secondary

Confusion Assessment Method

The Confusion Assessment Method (CAM) allows rapid assessment of the presence of delirium. Four clinical features, including 1) Acute onset and fluctuating course; 2) Inattention; 3) Disorganized thinking; and 4) Altered level of consciousness, are assessed. The presence of features 1 and 2 and either 3 or 4 indicates the patient has delirium. The positive and negative predictive values for the CAM are approximately 90%.

Time frame: Baseline only

Secondary

EuroQOL Five Dimensions Questionnaire (EQ-5D)

Patients will be asked to complete the EQ-5D once during the hospital stay, then at months 1, 3, 6, 9, and 12. The EQ-5D-3L is a well-validated measure of quality of life which enables the calculation of a single index value ranging from 0, worst imaginable health to 1, perfect health.

Time frame: One year

Secondary

Instrumental Activities of Daily Living (IADLs)

Level of independence with Instrumental Activities of Daily Living (IADLs) will be assessed at the same time points as the basic ADLs using the Lawton Index. The IADL index evaluates 8 domains of function including shopping, food preparation, housekeeping, laundry, transportation, handling finances, ability to take own medications and use of the telephone. A summary score ranges from 3 to 24, with higher scores indicating higher levels of independence with the tasks. Score options were trichotomous (1 = unable, 2 = needs assistance, 3 = independent).

Time frame: One year

ArmMeasureValue (MEAN)Dispersion
IntensiveInstrumental Activities of Daily Living (IADLs)14.0 score on a scaleStandard Deviation 3.32
Friendly VisitInstrumental Activities of Daily Living (IADLs)14.8 score on a scaleStandard Deviation 1.96
p-value: 0.02Regression, Linear
Secondary

Level of Hospital Mobility

All patients will wear a StepWatch throughout the hospitalization to document the level of mobility attained by each patient. The StepWatch is a ankle worn pedometer that documents number of steps taken and when they were taken.

Time frame: Average one week

Secondary

Lubben Social Network Scale (LSNS-Revised)

The Lubben Social Network Scale (LSNS) was designed to measure perceived social support received from family and friends. The LSNS-Revised includes 12 items with scores ranging from 0-60 with higher scores indicating greater perceived social support.

Time frame: One year

Secondary

Mini Cognitive Assessment (Mini-Cog)

The Mini-Cog is a brief cognitive screening measure that includes a three-item memory recall and a clock drawing test. The test is scored using a simple algorithm whereby patients who are unable to recall any of the three items are considered demented; those who can recall all three items are deemed not demented; and those with intermediate word recall ability (1 or 2 items) are classified based on the clock drawing test. For persons with intermediate recall ability, if the clock drawing is abnormal, the patient is considered demented and if the clock drawing is normal the patient is not considered demented.

Time frame: Baseline only

Secondary

Patient Health Questionnaire (PHQ) -2

Patients will be asked at each interview the Patient Health Questionnaire (PHQ) - 2, specifically 1) Have you often been bothered by feeling down, depressed, or hopeless?; and 2) Have you often been bothered by little interest or pleasure in doing things? The PHQ-2 has been found to have a sensitivity and specificity of 83% and 92% respectively and is an excellent brief screening tool for depression.

Time frame: One year

Secondary

Presence of Adverse Outcomes: Death

To determine the impact of participation in the mobility program on adverse outcomes, the investigators will measure the frequency of death in the MP versus UC groups.

Time frame: One year

Secondary

Presence of Adverse Outcomes (ED Visits, Rehospitalization, Nursing Home Placement, Death)

To determine the impact of participation in the mobility program on adverse outcomes, the investigators will measure the frequency of ED visits, hospitalizations as well as death and nursing home admissions including both short and long term placement in the MP versus UC groups.

Time frame: One year

Secondary

Presence of Adverse Outcomes: Nursing Home Placement

To determine the impact of participation in the mobility program on adverse outcomes, the investigators will measure the frequency of nursing home placement in the MP versus UC groups.

Time frame: One year

Secondary

Presence of Adverse Outcomes: Rehospitalization

To determine the impact of participation in the mobility program on adverse outcomes, the investigators will measure the frequency of rehospitalization in the MP versus UC groups.

Time frame: One Year

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026